Literature DB >> 19006783

Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy.

Karel Allegaert1, Tim van Mieghem, Rene Verbesselt, Jan de Hoon, Maissa Rayyan, Roland Devlieger, Jan Deprest, Brian J Anderson.   

Abstract

OBJECTIVE: To study cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. STUDY
DESIGN: Newly collected time-concentrations profiles and reported studies investigating cefazolin disposition (plasma, amniotic fluid) were pooled. Nonlinear mixed effect modeling was applied. A 2-compartment linear disposition model was used to fit cefazolin plasma observations. A third compartment was used to model amniotic fluid concentration.
RESULTS: One hundred eighty-seven plasma and 96 amniotic fluid samples were collected in 82 pregnancies (17-40 weeks gestational age). Cefazolin clearance and distribution estimates were 7.44 L/h and 12.04 L without gestational age-dependent trends in maternal plasma. The equilibration half-life (T(eq)) between plasma and amniotic fluid at term gestational age was 4.4 hours, increased with decreasing gestational age, and was 9.09 times longer in patients with polyhydramnios.
CONCLUSION: Cefazolin clearance and distribution volume are increased during pregnancy. The cefazolin T(eq) depends on gestational age and polyhydramnios. On the basis of these observations, dosing regimes to attain higher amniotic fluid concentrations were formulated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19006783     DOI: 10.1016/j.ajog.2008.08.067

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  Effect of Maternal Obesity on Maternal-Fetal Transfer of Preoperative Cefazolin at Cesarean Section.

Authors:  Stephanie McKenney Groff; Wareef Fallatah; Samuel Yang; Jamie Murphy; Christopher Crutchfield; Mark Marzinke; Joanne Kurtzberg; Carlton K K Lee; Irina Burd; Azadeh Farzin
Journal:  J Pediatr Pharmacol Ther       Date:  2017 May-Jun

Review 2.  Optimal administration of cefazolin prophylaxis for cesarean delivery.

Authors:  A Duffield; P Sultan; E T Riley; B Carvalho
Journal:  J Perinatol       Date:  2017-01       Impact factor: 2.521

Review 3.  Challenges in interventional radiology: the pregnant patient.

Authors:  Eunice K Moon; Weiping Wang; James S Newman; Maria Del Pilar Bayona-Molano
Journal:  Semin Intervent Radiol       Date:  2013-12       Impact factor: 1.513

Review 4.  Anatomical and physiological alterations of pregnancy.

Authors:  Jamil M Kazma; John van den Anker; Karel Allegaert; André Dallmann; Homa K Ahmadzia
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-02-06       Impact factor: 2.745

5.  Timing of Adjunctive Azithromycin for Unscheduled Cesarean Delivery and Postdelivery Infection.

Authors:  Ayodeji Sanusi; Yuanfan Ye; Kim Boggess; George Saade; Sherri Longo; Erin Clark; Sean Esplin; Kirsten Cleary; Ron Wapner; Michelle Owens; Sean Blackwell; Jeff M Szychowski; Alan T N Tita; Akila Subramaniam
Journal:  Obstet Gynecol       Date:  2022-05-02       Impact factor: 7.623

6.  Pharmacokinetics of ritodrine diastereomers in patients pregnant with singletons and twins.

Authors:  A Konda; T Ito; H Yoshida; T Toda; T Hayakawa; N Inotsume
Journal:  Eur J Clin Pharmacol       Date:  2009-05-27       Impact factor: 2.953

7.  Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery.

Authors:  Mohammed H Elkomy; Pervez Sultan; David R Drover; Ekaterina Epshtein; Jeffery L Galinkin; Brendan Carvalho
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

Review 8.  Pharmacokinetics of drugs in pregnancy.

Authors:  Maisa Feghali; Raman Venkataramanan; Steve Caritis
Journal:  Semin Perinatol       Date:  2015-11       Impact factor: 3.300

9.  Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy.

Authors:  J G Coen van Hasselt; Karel Allegaert; Kristel van Calsteren; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Biomed Res Int       Date:  2014-02-03       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.